Catalyst Event
Biogen Inc (BIIB) · Other
From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)
3/20/2026, 12:00:00 AM
Biogen and partner Eisai presented new real-world data at the AD/PD™ 2026 conference showing high long-term treatment persistence for LEQEMBI scheduled.
Korean Translation
AD/PD™ 2026 컨퍼런스에서 파트너사 에자이와 함께 레켐비(LEQEMBI)의 장기 치료 지속성이 높다는 새로운 실제 임상 데이터를 발표함. 이는 2026년 3월 20일로 예정됨.
Related Recent Events
Hewlett Packard Enterprise Co (HPE) · Other
HPE Discover Las Vegas 2026, the company's flagship annual event, is scheduled to begin, running from June 15-18. Major announcements on AI, cloud, and networking are anticipated to drive market interest scheduled.
6/15/2026, 12:00:00 AM
Hewlett Packard Enterprise Co (HPE) · Earnings Release
Fiscal Q2 2026 earnings release is expected. The company guided for revenue between $9.6 billion and $10.0 billion and non-GAAP EPS between $0.51 and $0.55. High volatility is anticipated based on historical earnings reactions expected.
6/2/2026, 12:00:00 AM
Biogen Inc (BIIB) · Other
FDA PDUFA action date for the supplemental Biologics License Application (sBLA) for a subcutaneous formulation of LEQEMBI is May 24, 2026; Medium importance is estimated due to uncertain market reaction scheduled.
5/24/2026, 12:00:00 AM
Target Corp (TGT) · Earnings Release
Q1 2026 earnings release scheduled for 2026-05-20 scheduled.
5/20/2026, 12:00:00 AM
NVIDIA Corporation (NVDA) · Earnings Release
NVIDIA's Q1 2027 earnings release is scheduled for May 20, 2026; Medium importance is assigned as earnings typically drive 5-10% volatility, and analysts forecast an EPS of $1.74-$1.76 estimated.
5/20/2026, 12:00:00 AM
ONEOK Inc (OKE) · Other
2026 Annual Meeting of Shareholders, which is expected to have low impact as a standard meeting, is scheduled.
5/20/2026, 12:00:00 AM